NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at the implementation of two brand-new patient registries on its proprietary NORD® IAMRARE® platform. This strategic initiative is designed to empower rare disease patient communities by providing them with the necessary digital infrastructure, technological backing, and institutional guidance to collect vital patient-reported data.
Funding for this significant undertaking is made available through the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®). The RDCA-DAP is a collaborative agreement established with the Critical Path Institute and is funded by the U.S. Food and Drug Administration (FDA). By bridging the gap between patient experiences and clinical research, this initiative seeks to accelerate the characterization of rare diseases and ultimately streamline the pathway toward effective therapy development for underserved patient populations.
The launch of these two registries underscores the expanding role of patient-driven data in modern medical research. In the landscape of rare diseases—where patient populations are often small, geographically dispersed, and poorly understood by conventional medical literature—direct insights from individuals living with these conditions are invaluable.
"This opportunity builds on NORD’s work supporting rare disease nonprofits," says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. "Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval."
Registry Implementation and Collaborative Support
Under the terms of the new request for applications, successful applicants will collaborate closely with NORD beginning in April 2027. The primary objective is to create, customize, and successfully launch a comprehensive patient registry tailored specifically to the unique needs of their respective rare disease community.
NORD’s involvement extends far beyond simple software provision. The organization will build and host the dedicated registry website, ensuring a secure, user-friendly digital environment for participants. Furthermore, NORD will deliver hands-on training to registry sponsors as they navigate the multifaceted process of establishing a registry advisory board and developing a robust study protocol.
Building a registry involves navigating complex regulatory and operational hurdles. To ease this burden, successful applicants will receive expert guidance on building and customizing surveys, navigating the often-intricate Institutional Review Board (IRB) process, and establishing clear, ethical criteria for sharing data collected by the registry with the broader scientific and research communities. This comprehensive support structure ensures that even smaller advocacy groups with limited technical resources can successfully execute high-quality, scientifically valid natural history studies.
Application Criteria and Timeline
Organizations interested in applying for this unique implementation opportunity must meet specific program criteria designed to ensure readiness and long-term sustainability. The request for applications is officially open, with a strict submission deadline set for January 10, 2027.
Following the close of the application window, submissions will be reviewed, and accepted applicants will be officially notified by February 1, 2027. Preparatory work and formal registry implementation will then kick off in April 2027. Eligible organizations seeking to apply can access the submission portal directly online. Any questions regarding the request for applications or the submission process should be directed to NORD’s designated program contact email.
About the NORD® IAMRARE® Platform
The NORD® IAMRARE® platform serves as a critical technological backbone for the rare disease community. Currently, the platform hosts over 55 live registries that are independently sponsored and managed by various patient advocacy organizations. The primary purpose of these registries is to systematically collect standardized, patient-reported data over time, creating a reliable foundation for natural history research. By capturing symptoms, disease progression, and treatment experiences directly from patients and caregivers, IAMRARE registries help transform anecdotal experiences into actionable scientific data.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP) is an innovative, FDA-sponsored initiative. It is designed to provide a centralized and standardized infrastructure that supports and accelerates the characterization of rare diseases. By aggregating diverse data sources and analytical tools, RDCA-DAP aims to foster a collaborative environment among researchers, regulators, and industry stakeholders, with the ultimate goal of expediting the development and regulatory review of novel therapies for rare conditions.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) stands as a leading independent, nonpartisan nonprofit organization dedicated to improving the health and lives of the more than 30 million Americans who are affected by rare diseases. NORD achieves its mission through a vast and influential network. It operates in partnership with more than 350 disease-specific member patient organizations, as well as 49 designated NORD Rare Disease Centers of Excellence. These centers span over 170 academic medical centers, specialized research institutions, and children’s hospitals located nationwide. Through these collaborative efforts, NORD continuously advances clinical care, innovative research, public education, and robust advocacy, striving to create a better, more hopeful future for every individual and family impacted by a rare disease.
